Lorus claimed that the drug has shown selective and potent antitumor activity in preclinical investigations with a variety of human cancers, including colon cancer and non-small cell lung cancer, and has demonstrated an excellent therapeutic window due to its low toxicity.
LOR-253 is a small molecule that has been optimised to inhibit a novel cancer target Metal-Responsive Transcription Factor 1 (MTF-1).
Following the approval, Lorus is now planning to initiate a dose escalation Phase I trial with LOR-253 in advanced or metastatic solid tumors.
The trial is expected to investigate the safety profile, tolerability, and antitumor activity of LOR-253 in cancer patients, as well as pharmacokinetic and pharmacodynamic properties of LOR-253.
Lorus said that the Phase I trial will be conducted at Memorial Sloan-Kettering Cancer Center in New York.